EyePoint (EYPT) Pharmaceuticals announced it has enrolled and randomized over 400 patients in the Phase 3 LUGANO pivotal trial of DURAVYU for the treatment of wet age-related macular degeneration exceeding its enrollment target. The seven-month enrollment for LUGANO represents one of the fastest enrolling Phase 3 pivotal trials for wet AMD to date.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint price target lowered to $26 from $30 at Mizuho
- EyePoint reports inducement grants under NASDAQ listing rule
- Positive Buy Rating for EyePoint Pharmaceuticals Driven by Clinical Progress and Strong Financial Position
- EyePoint Pharma’s Promising Q1 2025 Financial Results
- EyePoint Pharma’s Earnings Call Highlights Positive Momentum
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue